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ABSTRACT: The misfolding and aggregation of proteins into amyloid ﬁbrils characterizes many neurodegenerative disorders
such as Parkinson’s and Alzheimer’s diseases. We report here a method, termed SAVE (single aggregate visualization by
enhancement) imaging, for the ultrasensitive detection of individual amyloid ﬁbrils and oligomers using single-molecule
ﬂuorescence microscopy. We demonstrate that this method is able to detect the presence of amyloid aggregates of α-synuclein,
tau, and amyloid-β. In addition, we show that aggregates can also be identiﬁed in human cerebrospinal ﬂuid (CSF). Signiﬁcantly,
we see a twofold increase in the average aggregate concentration in CSF from Parkinson’s disease patients compared to age-
matched controls. Taken together, we conclude that this method provides an opportunity to characterize the structural nature of
amyloid aggregates in a key bioﬂuid, and therefore has the potential to study disease progression in both animal models and
humans to enhance our understanding of neurodegenerative disorders.
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Many neurodegenerative diseases share a commonunderlying process which involves the misfolding and
aggregation of a native soluble protein into insoluble deposits
that can accumulate in the brain and are accompanied by
progressive neuronal damage.1 Alzheimer’s disease (AD) and
Parkinson’s disease (PD) are the most common of these
disorders, together aﬀecting up to 8% of people over the age of
65 years. In AD, the amyloid-β (Aβ) peptide accumulates as
extracellular deposits, or plaques, and the protein tau as
intracellular inclusions, whereas in PD, α-synuclein (αS)
accumulates as Lewy bodies within neuronal cells. Despite
plaques and deposits being the most clearly evident character-
istics of the diseases, much evidence now points toward soluble
aggregate species as being the key cytotoxic agents.2−7 Due to
the highly heterogeneous nature and complexity of such
species, single-molecule ﬂuorescence techniques have proved to
be extremely useful for studying both the oligomers and ﬁbrils
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of amyloid proteins, as such methodologies can probe below
the ensemble average of the system, and characterize even the
rarest of species.3,6,8,9 Such techniques have, however, until
now, required the protein of interest to be covalently labeled
with an organic ﬂuorophore, which is not always straightfor-
ward and requires carefully controlled reactions to ensure that it
has no signiﬁcant eﬀect on the behavior of the protein.10,11 The
need for labeling makes it very challenging to apply single-
molecule ﬂuorescence techniques to samples of proteins
extracted from in vivo sources. To address these issues, we
have developed an approach to detect aggregates that does not
rely on covalently labeling proteins with organic ﬂuorophores,
but instead relies on addition of a dye that noncovalently binds
the oligomers and ﬁbrils, and not the monomeric protein. This
method, that we term SAVE (single aggregate visualization by
enhancement) imaging, uses highly sensitive single-molecule
instrumentation to detect the ﬂuorescence emission signal from
dye molecules that interact with the common motif of extended
β-sheet structure that is present in amyloid-related protein
aggregates.
The most commonly used assays for detecting amyloid ﬁbrils
exploits the binding of the benzothiazole salt thioﬂavin-T
(ThT) (Figure 1A) to amyloid structures, which leads to an
increase in its ﬂuorescence intensity by several orders of
magnitude, thereby making it an unusually sensitive and
eﬃcient reporter of extended β-sheet structure.12,13 Indeed, the
ﬂuorescence quantum yield, Φfl, of ThT in water at room
temperature is 1 × 10−4, but when docked between surface
side-chains in grooves running parallel to the long axis of the
cross β-sheets, the ﬂuorescence quantum yield increases by
many orders of magnitude, for example, Φfl = 0.43 for ThT
bound to amyloid ﬁbrils formed from insulin.14,15 Previous
work16,17 has used total internal reﬂection microscopy (TIRF)
combined with ThT ﬂuorescence to follow the elongation of
ﬁbrils in real-time. In this case, the species were several
micrometers in length and appeared as clear ﬁbril-like
structures in the images. It is generally thought that only ﬁbrils
contribute signiﬁcantly to an increase in the ﬂuorescence
intensity of ThT, since the smaller aggregates (particularly
those below the diﬀraction limit of light (∼250 nm)) have
fewer binding-sites. However, here we show that the high
detection eﬃciency of single-molecule techniques enables the
observation of an enhancement in ﬂuorescence through binding
both to ﬁbrils, and oligomers. Not only are we able to observe
the much smaller species in vitro, but similar aggregates can
also be detected in the cerebrospinal ﬂuid samples from people
both with and without Parkinson’s disease. This is the ﬁrst time,
to our knowledge, that ThT-active aggregates have been
detected in human CSF and opens up new possibilities to
understanding the cause of Parkinson’s disease and could also
be used as a method for early diagnosis.
■ RESULTS AND DISCUSSION
Monitoring the Aggregation of αS. To detect individual
protein aggregates, we have merged traditional bulk techniques
with single-molecule instrumentation, and have made use of
TIRF microscopy to detect and count individual ThT-bound
aggregates, one-by-one, generated from both in vitro and in
vivo sources. The success of this approach can be attributed to a
number of factors. First, as ThT is only signiﬁcantly ﬂuorescent
when bound to the underlying cross β-sheet structure of
amyloid, it can be added to a sample at high concentrations to
promote binding, but without generating high background
ﬂuorescence that prevents single-molecule detection. Second,
the unusually large Stokes shift (i.e., the wavelength diﬀerence
between the excitation and emission spectral maxima) of ThT
is exploited in the design of our instrumentation; excitation at
405 nm is coupled with detection of ﬂuorescence emission at
wavelengths greater than 500 nm. This strategy eﬀectively
ﬁlters out nonspeciﬁc sources of autoﬂuorescence that generally
have a smaller Stokes’ shift, while still allowing the detection of
even low amounts of ThT ﬂuorescence. In addition, the use of a
high numerical aperture objective lens, and a highly sensitive
electron multiplied charge coupled device (EMCCD) camera,
Figure 1. (A) Molecular structure of ThT. In the unbound state, ThT
has a low ﬂuorescence intensity; however, when bound to extended β-
sheet containing oligomers or ﬁbrils, the ﬂuorescence quantum yield
increases signiﬁcantly (more then 4000 fold). (B) Fluorescence
intensity of an individual αS aggregate. The red trace shows the AF647
ﬂuorescence, which decreases over time in stepwise drops, due to
photobleaching of each dye molecule. The green trace shows the
intensity of ThT, which remains constant over time, since exchange of
ThT occurs at a much higher rate than photobleaching of the
individual ThT molecules. (C) AF647 ﬂuorescence image of
monomeric αS. (D) SAVE image of monomeric αS, there are no
visible puncta, since ThT does not bind with an increase in
ﬂuorescence to monomeric protein. (E) AF647 image of aggregated
αS. The brighter puncta correspond to aggregates, and the dimmer
puncta monomeric protein. (F) SAVE images of the same regions as in
(E). Only the aggregates (bottom) give rise to ﬂuorescent signal, and
these correlate well with the brighter puncta in (E). The scale bars in
(C)−(F) are 5 μm and in the zoom are 500 nm in length. AF647
intensity histograms of labeled monomeric and aggregated αS are
shown in (G) and (H), respectively. As expected, the aggregated αS
has an intensity distribution shifted to higher values than for
monomeric αS.
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allows even those aggregates with extremely low ﬂuorescence
intensity to be successfully imaged.
The ability of SAVE imaging to detect protein aggregates is
ﬁrst demonstrated using αS covalently labeled with Alexa Fluor
647 (AF647) after incubation under conditions we have
previously shown to favor the formation of oligomers and
ﬁbrils.3 The use of labeled monomeric protein allows all αS-
containing species to be speciﬁcally imaged through excitation
and detection of AF647 ﬂuorophores. Figure 1B shows a typical
intensity trace of a single aggregate of AF647-labeled αS; the
AF647 intensity proﬁle (red) shows a series of stepwise
decreases, characteristic of photobleaching of the single
ﬂuorophores. In contrast, there is no noticeable photobleaching
of ThT (green trace) as the dye binding is transient, and so
there is a rapid turnover of ﬂuorescent molecules bound to the
aggregates. Therefore, even though the ThT signal is lower
than that from the AF647 ﬂuorescence, the lack of noticeable
photobleaching enables the imaging of the aggregates for
eﬀectively any length of time without being subjected to a
decrease in intensity. SAVE imaging takes advantage of this by
integrating the ﬂuorescence from the samples over several
seconds, during which time the aggregates remain bright,
whereas unwanted sources of ﬂuorescence photobleach.
Figure 1C and D shows the AF647 and SAVE images (same
region) of ﬂuorescently labeled monomeric αS. Although
multiple distinct puncta can be observed in the AF647 image,
no such signals are visible in the SAVE image, since monomeric
αS does not bind and enhance the ﬂuorescence of ThT. Figure
1E and F shows the AF647 and SAVE images of a mixture of
aggregated and monomeric αS. The brighter puncta in the
AF647 image appear as discrete puncta in the corresponding
SAVE image, and these can be attributed to αS aggregates.
Once again, the dimmer puncta in the AF647 image, which
correspond to monomeric αS, have no coincident puncta in the
SAVE image. One of the advantages of SAVE is that discrete
species can be identiﬁed and characterized, and Figure 1G and
H shows the intensity distribution from individual puncta
detected in the AF647 image of the monomeric and aggregated
αS, respectively. The red bars indicate the species detected in
which there is a coincident ﬂuorescence spot in the SAVE
image, whereas the gray are those in which there is no
coincident spot. As expected, the intensity distribution is shifted
to higher values for the coincident species, as these have
multiple labeled αS monomeric units present in them.
To test the ability of SAVE imaging to detect diﬀerent αS
species, wild-type αS without an added label was incubated
under conditions favoring its aggregation (Materials and
Methods), and samples were imaged at a range of time-points
(Figure 2). During the ﬁrst 2 h of the aggregation process, the
protein sample consisted mainly of monomeric species, and so
no ﬂuorescent puncta were observed. However, from 4 to 18 h,
ﬂuorescent puncta could be identiﬁed, and their numbers
increased over time. Due to the diﬀraction-limit of light, the
size of the oligomers cannot be deduced; however the puncta
must correspond to species <250 nm in size, and so are likely to
be either small extended β-sheet containing ﬁbrils, or
oligomers. These have been shown in previous work to be
highly cytotoxic to neuronal cells, resulting in increased reactive
oxygen species generation.3 The number of ﬂuorescent puncta
can be seen to increase over time such that, after 21 h, ﬁbrils
larger than 250 nm, and brighter than those at earlier time-
points are observed.
In addition to visualizing aggregates of αS, we explored the
ability of SAVE imaging to observe aggregates of the peptides
associated with AD, namely, Aβ and tau. Figure 3 shows the
AF647 and SAVE images when Aβ and tau were left to
aggregate for 3 h and 45 minutes, respectively. At early times,
the species are imaged as distinct puncta and correspond to
either small ﬁbrils (<250 nm), or oligomers. In the case of Aβ,
these oligomers have been shown to be highly cytotoxic to
neuronal cells.18
Limit of Detection of Oligomers. SAVE imaging was
evaluated using a concentrated sample of unlabeled αS
oligomers generated using a protocol that gives rise to >90%
of the monomer being incorporated into the oligomeric
species.19 The sizes and structural characteristics of the
oligomers were determined using the same set of established
biophysical techniques, described by Chen et al.,19 and repeated
here using atomic force microscopy (AFM) (Figure 4A),
dynamic light scattering (DLS) (Figure 4B), and circular
dichroism (CD) (Figure 4C) before being characterized by
Figure 2. SAVE images of αS species incubated under aggregating
conditions. At 2 h, no ﬂuorescent puncta were visible, since only
monomeric protein is present. However, after 4 h, diﬀraction-limited
puncta corresponding to oligomers or small ﬁbrils (<250 nm) become
visible. Eventually, after 21 h, larger ﬁbrillar species are present. Scale
bars are 5 μm and 500 nm in the zoomed insets.
Figure 3. SAVE images of AF647 labeled Aβ and tau aggregates. Aβ
was imaged via its AF647 ﬂuorescence (A) and using SAVE (B) after 3
h of aggregation at a concentration of 100 pM, and Tau via AF647
ﬂuorescence (C) and SAVE (D) after 45 minutes at a concentration of
37.5 pM. The brighter puncta in (A) and (C) are coincident with the
puncta in (B) and (D), respectively. Scale bars are 10 μm and 1 μm in
the zoomed insets. The green circles highlight example aggregated
species.
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SAVE imaging (Figure 5). The DLS data show that the
dominant species have hydrodynamic radii with a mean value of
∼13 nm, signiﬁcantly larger than that of a monomer (∼4 nm)
and the CD spectrum is intermediate between that of a
monomer and a β-sheet rich ﬁbrillar species. The AFM images
of the oligomers show only the presence of spherical species,
and no signs of ﬁbrillar fragments. An approximate concen-
tration of the oligomers was determined by measuring the
absorbance of the monomer, and by using the fact that, on
average, the oligomers contain 25 monomer units.19
To determine the limit of detection by SAVE imaging,
samples with a range of concentrations of the enriched
oligomers were diluted into 5 μM ThT solutions and the
resultant numbers of oligomers quantiﬁed by SAVE imaging
(Figure 5). At oligomer concentrations spanning 0.1−10 nM, a
linear relationship was observed between the concentration of
oligomers and the number of detected events. At low
concentrations (∼7 pM), the number of events detected
(1.69 × 10−3 ± 0.72 × 10−3 counts/μm2) is similar to that from
the background alone (0.72 × 10−3 ± 0.38 × 10−3 counts/μm2)
and so detecting oligomers becomes challenging. The limit of
blank (LoB) is the highest apparent number of counts expected
to be found when replicates of a sample containing no analyte
are detected, and is given by the expression:20
= + ×LoB mean blank 1.645 (SD of blank)
The limit of detection (LoD) was determined by utilizing both
the measured LoB and test replicates of a sample known to
contain a low concentration of analyte, and is deﬁned as
= + ×LoD LoB 1.645 (SD of low concentration sample)
The LoB was determined to be 1.35 × 10−3 oligomers/μm2,
and the LoD to be 2.52 × 10−3 counts/μm2. Therefore, this
method can accurately detect oligomers at concentrations as
low as ∼10 pM. At higher concentrations (∼100 nM), the
spatial separation of puncta in the ﬁeld of view becomes too
low, and resolving individual oligomers becomes problematic,
although this issue can be rectiﬁed through prior dilution of the
sample.
Detection of Aggregates in Bioﬂuids. The results
presented so far conﬁrm that SAVE imaging is able to detect
aggregates present in samples formed in vitro, and thus we
explored whether extended β-sheet containing aggregates could
be detected in human bioﬂuids formed in vivo. Single-molecule
detection of species in bioﬂuids is made diﬃcult as a result of
the inability to label speciﬁcally the biomolecule of interest, and
the high background ﬂuorescence that typically results from the
multiple components of the samples. CSF, however, is usually
free of any cells, and has a very low concentration of protein,
and so we observe negligible background signal. Additionally,
ThT becomes ﬂuorescent only when bound to molecules
containing an extended β-sheet structure typical of aggregates.
It is a combination of these factors that allows SAVE imaging to
speciﬁcally detect amyloid-like aggregates, and not monomeric
protein in CSF samples. CSF samples are likely to be the most
informative, since CSF is in closer contact with the central
nervous system than other more accessible ﬂuids, such as
Figure 4. (A) AFM image of enriched oligomers. (B) DLS peak for
monomer (blue), enriched oligomers (red), and ﬁbrils (green) (mean
from three measurements, error bars are from the standard deviation).
(C) CD spectra of monomer, enriched oligomers, and ﬁbrils.
Figure 5. (A) SAVE images of enriched oligomers at a range of
concentrations in 5 μM ThT. Scale bars are 5 μm B. Number of events
detected when a range of concentrations of enriched oligomers (mean
± SD, n = 30 images). There is a linear detection regime between 0.1
and 10 nM. At lower concentrations, the number of oligomers
detected is similar to the number of events detected from buﬀer alone,
while at higher concentrations, the ﬁeld-of-view is saturated, and
counting individual puncta becomes problematic.
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plasma, or urine, and so are more likely to reﬂect the
neurodegenerative processes relating to PD.
We have examined a series of CSF samples obtained via
lumbar puncture from healthy controls (HCs) and from
patients suﬀering from PD (the HC and PD samples were
previously obtained for a CSF biomarker study21). Samples
from the latter have previously been shown to contain both
monomeric and aggregated forms of αS,22,23 and we ﬁrst
measured the total concentration of αS in each of the samples
using ELISA methods (Figure 6E). Some reports in the
literature have suggested that the total concentration of αS is
lower in the CSF of PD patients compared to that from
HCs;24,25 our results, however, are in agreement with other
reports26−28 showing no signiﬁcant diﬀerences between the
sample sets. The total αS concentration, however, does not
necessarily reﬂect diﬀerences in the concentrations of speciﬁc
structural conformations of αS, including the potentially
damaging aggregated forms, limiting the utility on total αS as
a biomarker. We therefore used SAVE imaging to determine
whether or not the total aggregate load was diﬀerent between
samples from healthy controls and PD patients. ThT was added
to a ﬁnal concentration of 5 μM in samples of CSF diluted 1:10
in PBS, it was possible to observe ﬂuorescence signals in
samples from both PD patients (n = 18) and healthy controls
(HC) (n = 18) (Figure 6) that can be identiﬁed as aggregates
(Supporting Information Tables S2 and S3 provide sample
information, aggregate counts and intensities, and Figure 6
show the results from the analysis of the CSF samples). The
data also show that signiﬁcantly more puncta are, however,
detected in the SAVE images from the PD samples (0.013 ±
0.005 aggregates/μm2, mean ± SD) compared to those from
HCs (0.006 ± 0.004 aggregates/μm2, mean ± SD) giving rise
to a 95% conﬁdence interval: −0.01 to −0.004, p < 0.0001. In
addition, the distribution of integrated ﬂuorescence intensity
(or brightness) of the aggregates (Figure 6A) could be
determined by the technique. This distribution was found to
be shifted to higher values for the PD compared to the HC
samples, indicating either that the aggregates contained more
monomer units, or had a more ordered extended β-sheet
structure.
Previous studies of CSF samples using a dual-ELISA method
indicate that aggregated αS is signiﬁcantly more abundant in
CSF from PD patients than in those from healthy individuals,
or indeed, from those suﬀering from Alzheimer’s disease (AD),
or from progressive supranuclear palsy (PSP).29 Our results are
in broad agreement with these latter studies, as we have also
detected a higher concentration of extended β-sheet containing
aggregates in the CSF of PD patients compared to healthy
controls. These results indicate that the ultrasensitive detection
of aggregated protein in CSF is possible, and may, in addition,
diﬀerentiate between disease and nondisease states. In addition,
single-molecule methods have been combined with ﬂuores-
cently tagged antibodies to detect amyloid aggregates;30,31
however, as with ELISA studies, these methods rely on
immunocapture of the protein of interest, which can be
problematic. Single-molecule ﬂuorescence has also previously
Figure 6. (A) Photon count intensity distribution histograms from two representative samples of CSF (PD (red), sample 10; controls (blue), sample
23); these cases give rise to counts closest to mean for the PD and HC samples, respectively. (B) Representative TIRF images from sample 10 (red)
and sample 23 (blue). For each sample, 27 images were taken (three 3 × 3 grid scans), and the number of puncta counted. For sample 10, 1201
oligomers were detected, whereas for the HC, only 348 oligomers were observed. Green circles show detected oligomers. Scale bar is 5 μm in the
main images, and 500 nm in the zoomed image. (C) Histogram of mean number of oligomers for each sample, red bars are from PD CSF samples,
and blue from HC samples. (D) Box plots of the same data for the number of oligomers detected. Horizontal lines show the mean counts for PD and
HC samples. (E) Box plots of total αS concentrations from ELISA measurement.
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been used to detect the number of β-amyloid seeds present in
CSF, using seeded ampliﬁcation.32 In contrast to these previous
studies, SAVE imaging relies on the structural motif of the
extended crossed β-sheet, and so can directly detect aggregates
regardless of their protein composition and without ampliﬁca-
tion, providing a complementary measurement to ELISA. It
may be the case that this is a more relevant measure, since
neurodegenerative diseases may be due to a more general loss
of protein homeostasis,33 and so aggregates of a range of
proteins may result. SAVE imaging therefore provides a
sensitive measurement of the entire aggregate load in bioﬂuids,
and simultaneously allows the in-depth characterization of the
nature of these aggregates. The ability to visualize aggregates
directly in accessible in vivo ﬂuids provides the opportunity of
tracking the relationship between aggregate formation and
disease onset. This approach may be a valuable tool in future
studies of the progression of disease, therapeutics, or even early
diagnosis, all of which remain major hurdles to neuro-
degenerative diseases. A limitation of this technique is that it
is unable to determine which proteins the aggregates are
composed of
■ CONCLUSION
In this paper, we have discussed the development of a method
for directly visualizing unlabeled aggregates with extended cross
β-sheet structure at the single-molecule level and that we can
straightforwardly detect enriched oligomers, containing on
average 25 monomers. In addition to imaging in vitro oligomer
formation, we have also shown that SAVE imaging can be used
to characterize aggregates present in human bioﬂuids, and we
demonstrate that CSF from PD patients contains a signiﬁcantly
higher number of aggregates than CSF from healthy controls.
Unlike ELISA-based methods, SAVE imaging detects a generic
structural motif rather than a speciﬁc epitope of a particular
proteins. As we analyze aggregates one-by-one, diﬀerences in
their ﬂuorescence intensities can be measured, and this may
provide insights into their structural nature, information that is
very diﬃcult to very to obtain using traditional ensemble-based
techniques. The results show that this method has the potential
to be used to study, in great detail, unlabeled aggregates formed
in vitro, and hence to deﬁne the intrinsic kinetics and
mechanism of aggregate formation, in addition to providing
new insights into the role of oligomers in the onset and
progression of disease. Furthermore, this method may act as a
diagnostic tool for neurodegeneration, an advance that is critical
for the implementation of clinical trials, and for monitoring the
eﬀectiveness of potential therapies.
■ METHODS
Preparation of αS. Either the wild-type or A90C variant (for
labeled αS) of monomeric αS was puriﬁed from Escherichia coli as
described previously.3,34 For A90C, the single cysteine was labeled
with maleimide-modiﬁed Alexa Fluor 647 (AF647) as previously
reported.35 The excess dye was removed by passing the labeled protein
through a P10 desalting column containing Sephadex G25 matrix (GE
Healthcare, Waukesha, WI). The protein was concentrated using
Amicon Ultra Centricons (Millipore, Billerica, MA), divided into
aliquots, before being ﬂash-frozen in liquid nitrogen and stored at −80
°C. Each aliquot was only thawed once prior to use.
Aggregation of αS. For the aggregation reactions, a 70 μM
solution of either wild-type or AF647 labeled αS in 25 mM Tris buﬀer
(pH 7.4) and 0.1 M NaCl (with 0.01% NaN3 to prevent bacterial
growth during the experiments) was incubated in the dark at 37 °C,
with constant agitation at 200 rpm for 5 days, during which time
aliquots were taken.
Aggregation of Amyloid Beta and Tau. To demonstrate the
ability to visualize aggregates from other proteins that form extended
β-sheet aggregates, we also incubated AF647 labeled cys-Aβ1−42 (500
nM in SSPE buﬀer (Fluka), pH 7.4, at 37 °C with constant agitation at
200 rpm), and AF647 labeled K18 tau ΔK (10 μM in 50 mM
ammonium acetate buﬀer, pH 7, with 2 μM heparin and 1 mM DTT
at 37 °C) as described previously.9,36
Preparation of Enriched Oligomers. A solution of monomeric
αS at ca. 800 μM (12 mg/mL) was incubated in PBS at 37 °C without
agitation for 20−24 h. The solution was then passed through a 0.22
μm cutoﬀ ﬁlter (Millipore, product number SLGP033RK) to remove
any particles of dust and/or large protein aggregates that may have
been present. The monomeric fraction of the solution (>95%) is
removed from the oligomers of αS by passing the solution through a
series of 100 kDa cutoﬀ ﬁlters (Millipore, product number
UFC5100BK). The concentration of the ﬁnal oligomeric solution
was estimated from the absorbance at 275 nm, using an extinction
coeﬃcient of 5600 M−1 cm−1.
Characterization of Enriched Oligomers. AFM. AFM images of
αS oligomers were taken using a Nanowizard II atomic force
microscope (JPK, Berlin, Germany). Images were acquired at room
temperature in air using tapping mode. αS oligomers (∼1 μM, 10 μL)
were deposited on freshly cleaved mica, incubated for 10 minutes,
followed by washes with deionized water, and left to dry in air.
CD. Far-UV CD spectra of the αS oligomers were acquired in PBS
at 20 °C. Proteins were diluted to a ﬁnal concentration of ∼10 μM,
and the spectra were acquired using a 1 mm path length cuvette and a
J-810 Jasco spectropolarimeter (Tokyo, Japan), equipped with a
thermostatic cell holder.
DLS. The intensity-weighted mean hydrodynamic diameter with
polydispersity index PdI (a parameter used to describe the width of the
size distribution) and the diameter number distribution proﬁle of
oligomeric αS (35 μM) in PBS at 25 °C were determined by DLS
using a Zetasizer Nano ZSP (Malvern Instruments) at a back
scattering angle of 173°.
Preparation of ThT Solution. ThT stock solutions were prepared
by diluting ThT (Sigma-Aldrich, product number T3516) into neat
ethanol (Sigma-Aldrich, product number 459836) to give a ﬁnal
concentration of ∼1 M. Following this, a 100-fold dilution into
preﬁltered PBS (0.02 μm syringe ﬁlter, Whatman, product number
6809−2101) was performed to give an ∼100 μM stock solution of
ThT. It was important to ensure that the ThT solutions were freshly
ﬁltered each day, and that the concentrations of the stocks were not
too high, since insoluble ThT can give rise to ﬂuorescent puncta. The
ﬁnal concentration was determined from the absorbance at 412 nm,
using an extinction coeﬃcient of 36 000 M−1 cm−1. The stock solution
was stored in the dark at 4 °C, and was only used for a maximum of 2
weeks after preparation.
Preparation of Slides for Single-Molecule Analysis. Borosili-
cate glass coverslips (VWR international, 20 × 20 mm, product
number 63 1-0122) were cleaned using an argon plasma cleaner
(PDC-002, Harrick Plasma) for at least 1 h to remove any ﬂuorescent
residues. Frame-Seal slide chambers (9 × 9 mm2, Biorad, Hercules,
CA, product number SLF-0601) were aﬃxed to the glass, and 50 μL of
poly-L-lysine (70 000−150 000 molecular weight, Sigma-Aldrich,
product number P4707-50 ML) was added to the coverslide on the
inside of the chamber and incubated for at least 30 minutes, before
being washed with 20 nm ﬁltered PBS buﬀer (phosphate buﬀered
saline tablets, Sigma-Aldrich, product number P4417) which had been
prebleached in a bespoke solvent bleacher set at 470 nm light
overnight. Prior to use, each batch of coverslides were tested for
ﬂuorescent artifacts (i.e., false positives) by analyzing a solution of 5
μM ThT only. We found that the poly-L-lysine solution degraded over
time, leading to ﬂuorescent artifacts, and so only fresh solutions of this
were used.
Single-Molecule Imaging. Imaging was performed using a home-
built total internal reﬂection ﬂuorescence microscope. This imaging
mode restricts detectable ﬂuorescence signal to within 200 nm from
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the sample slide. For imaging of AF647 labeled αS in the presence of
ThT, the output from two lasers operating at 405 nm (Oxxius
LaserBoxx, product number LBX-405-100-CIR-PP) and 640 nm
(Coherent Cube, product number 1150205) were aligned and directed
parallel to the optical axis at the edge of a 1.49 NA TIRF objective
(APON60XO TIRF, Olympus, product number N2709400), mounted
on an inverted Olympus IX-71 microscope. Fluorescence was collected
by the same objective was separated from the returning TIR beam by a
dichroic (Di01-R405/488/561/635, Semrock), and passed through
appropriate ﬁlters (BLP01-488R and BLP01-635R, Semrock). The
ﬂuorescence was then passed through a 2.5× beam expander and dual-
view (Photometrics). The images were recorded on an EMCCD
camera (Evolve 512, Photometrics) operating in frame transfer mode
(EMGain of 11.5 e−/ADU and 250 ADU/photon). Each pixel was 109
nm in length. For each data set, 3 × 3 image grids were measured in
three diﬀerent regions of the coverslide. The distance between the
nine images measured in each grid was set to 350 μm, and was
automated (bean-shell script, Mircomanager) to prevent user bias.
Images were recorded at 33 frames s−1 for 150 frames ﬁrst from the
red channel (AF647 emission) with 640 nm illumination (10−50 W/
cm2), followed by 150 frames in the blue channel (ThT emission) with
405 nm illumination (150−200 W/cm2). For unlabeled oligomers,
either from the enriched preparation, or those present in CSF, the
sample was only excited with 405 nm illumination, and images were
recorded from the blue channel only. All samples were stored and
diluted in LoBind microcentrifuge (Eppendorf, Hamburg, Germany)
to limit surface adsorption, as shown to be successful in our previous
work.37,38
CSF Samples. CSF samples were collected from 18 patients with
clinically deﬁned PD (aged 51−85 years, mean ± SD = 66 ± 8) and 18
normal healthy individuals (aged 46−71 years, mean ± SD = 61 ± 9)
by lumbar puncture (sample information is given in Supporting
Information Figures S4 and S5). The HC and PD samples were
previously obtained for a CSF biomarker study.21 A standardized
protocol for the collection and storage of CSF (www.neurochem.gu.
se/TheAlzAssQCProgram) was followed. Brieﬂy, lumbar puncture was
performed between 9 and 12 a.m. A volume of 15 mL of CSF was
collected in sterile polypropylene tubes. The collected CSF samples
were gently mixed to avoid gradient eﬀects and centrifuged in the
original tube at 4000 rpm for 10 minutes at +4 °C. It was then divided
into 0.5 mL aliquots that were frozen on dry ice and stored at −80 °C
in LoBind microcentrifuge tubes (Eppendorf, Hamburg, Germany)
pending analysis. Blood-contaminated samples (>500 red blood cells
per μL) were excluded. Time between sample collection, centrifuga-
tion, and freezing was maximum 1 h. The patients were diagnosed
according to the UK PD Society Brain Bank Criteria. The study was
conducted in accordance with local clinical research regulations and
with the provisions of the Helsinki declaration. An informed consent
was obtained from all subjects, including access to their clinical data.
CSF samples were analyzed for total αS using the αS ELISA Kit
(Covance, Berkeley, CA) according to kit insert instructions.
Prior to SAVE imaging, the CSF samples were diluted 10-fold into
preﬁltered PBS (0.02 μm syringe ﬁlter, Whatman, product number
6809-2101) and ThT was added to give a ﬁnal concentration of 5 μM.
The sample was then added to the preprepared borosilicate slides, and
incubated for 10 minutes before being imaged as described previously.
■ ASSOCIATED CONTENT
*S Supporting Information
The Supporting Information is available free of charge on the
ACS Publications website at DOI: 10.1021/acschemneur-
o.5b00324.
Data analysis; optimum concentration for SAVE imaging;
optimum threshold for spot counting; patient sample
information (PDF)
■ AUTHOR INFORMATION
Corresponding Author
*E-mail: dk10012@cam.ac.uk.
Present Address
∇M.K.: iNANO, Aarhus University, Gustav Wieds Vej 14, DK-
8000 Aarhus C, Denmark.
Author Contributions
⊥M.H.H. and S.F.L. contributed equally to this work.
M.H.H. and S.F.L. performed experiments and wrote the
manuscript. S.G., M.J.D., L.T., M.K., J.S.B., and M.I. aided with
experiments and contributed to writing the manuscript. S.W.C.
provided enriched oligomer samples and performed the
biophysical characterization of them. N.K.M. performed CSF
sample collection/preparation and helped with the initial
analysis of the data. H.Z. performed the ELISAs on the CSF
samples. M.H.H., S.F.L., D.K., N.W., N.C., and C.M.D.
designed experiments.
Funding
This research study was funded in part by the Wellcome Trust/
MRC Joint Call in Neurodegeneration award (WT089698) to
the UK Parkinson’s Disease Consortium (UKPDC) and the
NIHR rare disease translational research collaboration and
supported by the National Institute for Health Research
University College London Hospitals Biomedical Research
Centre. We are also grateful to the Augustus Newman and
Wolfson Foundations for their support. We thank the Royal
Society for the University Research Fellowship of Dr. Steven F.
Lee (UF120277).
Notes
The authors declare no competing ﬁnancial interest.
■ REFERENCES
(1) Chiti, F., and Dobson, C. M. (2006) Protein Misfolding,
Functional Amyloid, and Human Disease. Annu. Rev. Biochem. 75,
333−366.
(2) Winner, B., Jappelli, R., Maji, S. K., Desplats, P. A., Boyer, L.,
Aigner, S., Hetzer, C., Loher, T., Vilar, M., Campioni, S., et al. (2011)
In Vivo Demonstration That Alpha-Synuclein Oligomers Are Toxic.
Proc. Natl. Acad. Sci. U. S. A. 108, 4194−4199.
(3) Cremades, N., Cohen, S. I. A., Deas, E., Abramov, A. Y., Chen, A.
Y., Orte, A., Sandal, M., Clarke, R. W., Dunne, P., Aprile, F. A., et al.
(2012) Direct Observation of the Interconversion of Normal and
Toxic Forms of α-Synuclein. Cell 149, 1048−1059.
(4) Outeiro, T. F., Putcha, P., Tetzlaff, J. E., Spoelgen, R., Koker, M.,
Carvalho, F., Hyman, B. T., and McLean, P. J. (2008) Formation of
Toxic Oligomeric Alpha-Synuclein Species in Living Cells. PLoS One 3,
e1867.
(5) Billings, L. M., Oddo, S., Green, K. N., McGaugh, J. L., and
LaFerla, F. M. (2005) Intraneuronal Abeta Causes the Onset of Early
Alzheimer’s Disease-Related Cognitive Deficits in Transgenic Mice.
Neuron 45, 675−688.
(6) Cleary, J. P., Walsh, D. M., Hofmeister, J. J., Shankar, G. M.,
Kuskowski, M. A., Selkoe, D. J., and Ashe, K. H. (2005) Natural
Oligomers of the Amyloid-Beta Protein Specifically Disrupt Cognitive
Function. Nat. Neurosci. 8, 79−84.
(7) Koffie, R. M., Meyer-Luehmann, M., Hashimoto, T., Adams, K.
W., Mielke, M. L., Garcia-Alloza, M., Micheva, K. D., Smith, S. J., Kim,
M. L., Lee, V. M., et al. (2009) Oligomeric Amyloid Beta Associates
with Postsynaptic Densities and Correlates with Excitatory Synapse
Loss near Senile Plaques. Proc. Natl. Acad. Sci. U. S. A. 106, 4012−
4017.
(8) Zijlstra, N., Blum, C., Segers-Nolten, I. M. J., Claessens, M. M. A.
E., and Subramaniam, V. (2012) Molecular Composition of Sub-
Stoichiometrically Labeled α-Synuclein Oligomers Determined by
ACS Chemical Neuroscience Research Article
DOI: 10.1021/acschemneuro.5b00324
ACS Chem. Neurosci. 2016, 7, 399−406
405
Single-Molecule Photobleaching. Angew. Chem., Int. Ed. 51, 8821−
8824.
(9) Narayan, P., Meehan, S., Carver, J. A., Wilson, M. R., Dobson, C.
M., and Klenerman, D. (2012) Amyloid-β Oligomers Are Sequestered
by Both Intracellular and Extracellular Chaperones. Biochemistry 51,
9270−9276.
(10) Yoshina-Ishii, C., Chan, Y.-H. M., Johnson, J. M., Kung, L. A.,
Lenz, P., and Boxer, S. G. (2006) Diffusive Dynamics of Vesicles
Tethered to a Fluid Supported Bilayer by Single-Particle Tracking.
Langmuir 22, 5682−5689.
(11) Saxton, M. J., and Jacobson, K. (1997) Single-Particle Tracking:
Applications to Membrane Dynamics. Annu. Rev. Biophys. Biomol.
Struct. 26, 373−399.
(12) Maskevich, A. A., Stsiapura, V. I., Kuzmitsky, V. A., Kuznetsova,
I. M., Povarova, O. I., Uversky, V. N., and Turoverov, K. K. (2007)
Spectral Properties of Thioflavin T in Solvents with Different
Dielectric Properties and in a Fibril-Incorporated Form. J. Proteome
Res. 6, 1392−1401.
(13) LeVine, H., 3rd (1993) Thioflavine T Interaction with Synthetic
Alzheimer’s Disease Beta-Amyloid Peptides: Detection of Amyloid
Aggregation in Solution. Protein Sci. 2, 404−410.
(14) Sulatskaya, A. I., Maskevich, A. A., Kuznetsova, I. M., Uversky,
V. N., and Turoverov, K. K. (2010) Fluorescence Quantum Yield of
Thioflavin T in Rigid Isotropic Solution and Incorporated into the
Amyloid Fibrils. PLoS One 5, e15385.
(15) Biancalana, M., and Koide, S. (2010) Molecular Mechanism of
Thioflavin-T Binding to Amyloid Fibrils. Biochim. Biophys. Acta,
Proteins Proteomics 1804, 1405−1412.
(16) Ban, T., Hamada, D., Hasegawa, K., Naiki, H., and Goto, Y.
(2003) Direct Observation of Amyloid Fibril Growth Monitored by
Thioflavin T Fluorescence. J. Biol. Chem. 278, 16462−16465.
(17) Ban, T., Hoshino, M., Takahashi, S., Hamada, D., Hasegawa, K.,
Naiki, H., and Goto, Y. (2004) Direct Observation of Aβ Amyloid
Fibril Growth and Inhibition. J. Mol. Biol. 344, 757−767.
(18) Narayan, P., Holmström, K. M., Kim, D.-H., Whitcomb, D. J.,
Wilson, M. R., St. George-Hyslop, P., Wood, N. W., Dobson, C. M.,
Cho, K., Abramov, A. Y., et al. (2014) Rare Individual Amyloid-β
Oligomers Act on Astrocytes to Initiate Neuronal Damage.
Biochemistry 53, 2442−2453.
(19) Chen, W. S., Drakulicb, S., Deas, E., and Cremades, N. (2015)
Structural Characterization of Toxic Oligomers That Are Kinetically
Trapped during α-Synuclein Fibril Formation. Proc. Natl. Acad. Sci.
U.S.A. 112, E1994−E2003.
(20) Armbruster, D. A., and Pry, T. (2008) Limit of Blank, Limit of
Detection and Limit of Quantitation. Clin. Biochem. Rev. 29, S49−S52.
(21) Magdalinou, N. K., Paterson, R. W., Schott, J. M., Fox, N. C.,
Mummery, C., Blennow, K., Bhatia, K., Morris, H. R., Giunti, P.,
Warner, T. T., et al. (2015) A Panel of Nine Cerebrospinal Fluid
Biomarkers May Identify Patients with Atypical Parkinsonian
Syndromes. J. Neurol., Neurosurg. Psychiatry 86, 1240−1247.
(22) Tokuda, T., Qureshi, M. M., Ardah, M. T., Varghese, S., Shehab,
S. a. S., Kasai, T., Ishigami, N., Tamaoka, A., Nakagawa, M., and El-
Agnaf, O. M. A. (2010) Detection of Elevated Levels of α-Synuclein
Oligomers in CSF from Patients with Parkinson Disease. Neurology 75,
1766−1772.
(23) El-Agnaf, O. M. A., Salem, S. A., Paleologou, K. E., Curran, M.
D., Gibson, M. J., Court, J. A., Schlossmacher, M. G., and Allsop, D.
(2006) Detection of Oligomeric Forms of Alpha-Synuclein Protein in
Human Plasma as a Potential Biomarker for Parkinson’s Disease.
FASEB J. 20, 419−425.
(24) Mollenhauer, B., Cullen, V., Kahn, I., Krastins, B., Outeiro, T. F.,
Pepivani, I., Ng, J., Schulz-Schaeffer, W., Kretzschmar, H. A., McLean,
P. J., et al. (2008) Direct Quantification of CSF Alpha-Synuclein by
ELISA and First Cross-Sectional Study in Patients with Neuro-
degeneration. Exp. Neurol. 213, 315−325.
(25) Tokuda, T., Salem, S. A., Allsop, D., Mizuno, T., Nakagawa, M.,
Qureshi, M. M., Locascio, J. J., Schlossmacher, M. G., and El-Agnaf, O.
M. A. (2006) Decreased Alpha-Synuclein in Cerebrospinal Fluid of
Aged Individuals and Subjects with Parkinson’s Disease. Biochem.
Biophys. Res. Commun. 349, 162−166.
(26) Noguchi-Shinohara, M., Tokuda, T., Yoshita, M., Kasai, T., Ono,
K., Nakagawa, M., El-Agnaf, O. M. A., and Yamada, M. (2009) CSF
Alpha-Synuclein Levels in Dementia with Lewy Bodies and
Alzheimer’s Disease. Brain Res. 1251, 1−6.
(27) Reesink, F. E., Lemstra, A. W., van Dijk, K. D., Berendse, H. W.,
van de Berg, W. D. J., Klein, M., Blankenstein, M. A., Scheltens, P.,
Verbeek, M. M., and van der Flie, W. M. (2010) CSF α-Synuclein
Does Not Discriminate Dementia with Lewy Bodies from Alzheimer’s
Disease. Alzheimer's Dementia 22, 87−95.
(28) Spies, P. E., Melis, R. J. F., Sjögren, M. J. C., Rikkert, M. G. M.
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